Products
Ozekibart Biosimilar VH-IgG Antibody (DR5) for Research
Cat No.: GMP-Bios-INN-1321
Anti-TNFRSF10B/CD262/DR5/TRAILR2 therapeutic antibody (Pre-made Ozekibart biosimilar,VH-IgG) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Ozekibart (development code AZD8853) is a VH-IgG format monoclonal antibody targeting TNFRSF10B (TRAIL-R2). It is developed by AstraZeneca. It is in Phase I clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1321-1mg | 1mg | 3090 |
| GMP-Bios-INN-1321-10mg | 10mg | |
| GMP-Bios-INN-1321-100mg | 100mg | |
| GMP-Bios-INN-1321-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Ozekibart biosimilar, VH-IgG, Anti-TNFRSF10B/CD262/DR5/TRAILR2 Antibody: Anti-DR5/TNFRSF10B/CD262/TRAIL-R2 therapeutic antibody |
| INN Name | Ozekibart |
| Target | TNFRSF10B/CD262/DR5/TRAILR2 |
| Format | VH-IgG |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | na |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | AstraZeneca |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Solid tumours |
| Production | na |
| Development Tech | na |
